Pancreas fistula risk prediction: implications for hospital costs and payments

详细信息    查看全文

• 作者：Daniel E. Abbott¹ ; ^{abbott@surgery.wisc.edu} ; Ching Wei D. Tzeng² ; Matthew T. McMillan³ ; Mark P. Callery⁴ ; Tara S. Kent⁴ ; John D. Christein⁵ ; Stephen W. Behrman⁶ ; Daniel P. Schauer⁷ ; Dennis J. Hanseman⁷ ; Mark H. Eckman⁷ ; Charles M. Vollmer³
• 刊名：HPB
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：19
• 期：2
• 页码：140-146
• 全文大小：332 K
• 卷排序：19

文摘

As payment models evolve, disease-specific risk stratification may impact patient selection and financial outcomes. This study sought to determine whether a validated clinical risk score for post-operative pancreatic fistula (POPF) could predict hospital costs, payments, and profit margins.MethodsA multi-institutional cohort of 1193 patients undergoing pancreaticoduodenectomy (PD) were matched to an independent hospital where cost, in US$, and payment data existed. An analytic model detailed POPF risk and post-operative sequelae, and their relationship with hospital cost and payment.ResultsPer-patient hospital cost for negligible-risk patients was $37,855. Low-, moderate-, and high- risk patients had incrementally higher hospital costs of $38,125 ($270; 0.7% above negligible-risk), $41,128 ($3273; +8.6%), and $41,983 ($3858; +10.9%), respectively. Similarly, hospital payment for negligible-risk patients was $42,685/patient, with incrementally higher payments for low-risk ($43,265; +1.4%), moderate-risk ($45,439; +6.5%) and high-risk ($46,564; +9.1%) patients. The lowest 30-day readmission rates – with highest net profit – were found for negligible/low-risk patients (10.5%/11.1%), respectively, compared with readmission rates of moderate/high-risk patients (15%/15.7%).ConclusionFinancial outcomes following PD can be predicted using the FRS. Such prediction may help hospitals and payers plan for resource allocation and payment matched to patient risk, while providing a benchmark for quality improvement initiatives.